explore -WSS

explore

author：explore 2025-10-04 11:35:54 - browse：8

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Wildfire pollution widens asthma inequities on Long Island

entertainment

explore

WSS

Vertex non

Mitch McConnell episode has important public health takeaway

What the airline industry can learn from medicine

Micronoma's microbiome cancer diagnostic approach under fire

Millions may soon lose Medicaid when they don't have to

Micronoma's microbiome cancer diagnostic approach under fire

entertainment

explore

focus

Hepatitis C has a cure — but many Americans still lack access to it

Novo pauses ads for weight loss drug Wegovy amid demand

Heart attack and stroke risk calculators need revising

Mitch McConnell episode has important public health takeaway

Psychedelics group wrestles with new pharma identity

Millions may soon lose Medicaid when they don't have to

Malaria cases in Florida and Texas: Here’s what you need to know

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Medicare details structure of new drug price negotiation program

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

explore

Inside the rise of 'mukbang' eating videos

How to fix the rural physician shortage in the U.S.

Bispecific antibodies are next new thing in cancer immunotherapy

Micronoma's microbiome cancer diagnostic approach under fire

FDA approves first new drug developed for postpartum depression

Mega Millions pot grows to $1.25 billion after no winner

leisure time

entertainment

explore

knowledge